These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32472084)

  • 1. Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission.
    Machova Polakova K; Zizkova H; Zuna J; Motlova E; Hovorkova L; Gottschalk A; Glauche I; Koblihova J; Pecherkova P; Klamova H; Stastna Markova M; Srbova D; Benesova A; Polivkova V; Jurcek T; Zackova D; Mayer J; Ernst T; Mahon FX; Saussele S; Roeder I; Cross NCP; Hochhaus A
    Leukemia; 2020 Aug; 34(8):2113-2124. PubMed ID: 32472084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
    Bernardi S; Malagola M; Zanaglio C; Polverelli N; Dereli Eke E; D'Adda M; Farina M; Bucelli C; Scaffidi L; Toffoletti E; Deambrogi C; Stagno F; Bergamaschi M; Franceschini L; Abruzzese E; Divona MD; Gobbi M; Di Raimondo F; Gaidano G; Tiribelli M; Bonifacio M; Cattaneo C; Iurlo A; Russo D
    Cancer Med; 2019 May; 8(5):2041-2055. PubMed ID: 30950237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring Treatment-Free Remission by Droplet Digital PCR in CML Patients with Deep Molecular Response to Tyrosine Kinase Inhibitor: An Analysis Based on Real-World Data.
    Zhu G; Yang Y; Wang H; Xie J; Hu J; Guo W; Zhang L; Liu Z; Chen X; Chang J; Xu J; Tan Y
    Ann Clin Lab Sci; 2020 Sep; 50(5):591-599. PubMed ID: 33067205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort.
    Saugues S; Lambert C; Daguenet E; Roth-Guepin G; Huguet F; Cony-Makhoul P; Ansah HJ; Escoffre-Barbe M; Turhan A; Rousselot P; Tchirkov A; Hamroun D; Hermet E; Pereira B; Berger MG
    Haematologica; 2024 Sep; 109(9):2893-2907. PubMed ID: 38695126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients.
    Kockerols C; Valk PJM; Janssen JJWM; Hogenbirk P; Cornelissen JJ; Saussele S; Spiess B; Perusini MA; Kim D; Westerweel PE
    Eur J Haematol; 2024 Nov; 113(5):606-613. PubMed ID: 38994654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
    Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.
    Clark RE; Polydoros F; Apperley JF; Milojkovic D; Rothwell K; Pocock C; Byrne J; de Lavallade H; Osborne W; Robinson L; O'Brien SG; Read L; Foroni L; Copland M
    Lancet Haematol; 2019 Jul; 6(7):e375-e383. PubMed ID: 31201085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
    Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
    Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission.
    Pagani IS; Dang P; Saunders VA; Grose R; Shanmuganathan N; Kok CH; Carne L; Rwodzi Z; Watts S; McLean J; Braley J; Altamura H; Yeung DT; Branford S; Yong ASM; White DL; Hughes TP; Ross DM
    Leukemia; 2020 Apr; 34(4):1052-1061. PubMed ID: 31768016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of molecular responses based on BCR-ABL1% (IS) results from an in-house TaqMan-based qPCR versus Xpert(®) assay in CML patients on tyrosine kinase inhibitor therapy.
    Boeckx N; Laer CV; Roover JD; Wilmsen B; Bruyninckx K; Pauwels S
    Acta Clin Belg; 2015 Aug; 70(4):237-43. PubMed ID: 26166681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.
    Shanmuganathan N; Pagani IS; Ross DM; Park S; Yong ASM; Braley JA; Altamura HK; Hiwase DK; Yeung DT; Kim DW; Branford S; Hughes TP
    Blood; 2021 Mar; 137(9):1196-1207. PubMed ID: 32871588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.
    Breccia M; Efficace F; Colafigli G; Scalzulli E; Di Prima A; Martelli M; Foà R
    Expert Rev Hematol; 2020 Dec; 13(12):1311-1318. PubMed ID: 33205694
    [No Abstract]   [Full Text] [Related]  

  • 13. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
    Rea D; Nicolini FE; Tulliez M; Guilhot F; Guilhot J; Guerci-Bresler A; Gardembas M; Coiteux V; Guillerm G; Legros L; Etienne G; Pignon JM; Villemagne B; Escoffre-Barbe M; Ianotto JC; Charbonnier A; Johnson-Ansah H; Noel MP; Rousselot P; Mahon FX;
    Blood; 2017 Feb; 129(7):846-854. PubMed ID: 27932374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
    Ankathil R; Ismail SM; Mohd Yunus N; Sulong S; Husin A; Abdullah AD; Hassan R
    Malays J Pathol; 2020 Dec; 42(3):307-321. PubMed ID: 33361712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E14a2
    Claudiani S; Apperley JF; Gale RP; Clark R; Szydlo R; Deplano S; Palanicawandar R; Khorashad J; Foroni L; Milojkovic D
    Haematologica; 2017 Aug; 102(8):e297-e299. PubMed ID: 28495914
    [No Abstract]   [Full Text] [Related]  

  • 16. When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia.
    Laneuville P
    Curr Treat Options Oncol; 2018 Mar; 19(3):15. PubMed ID: 29520446
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Pagani IS; Dang P; Kommers IO; Goyne JM; Nicola M; Saunders VA; Braley J; White DL; Yeung DT; Branford S; Hughes TP; Ross DM
    Haematologica; 2018 Dec; 103(12):2026-2032. PubMed ID: 29976745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA.
    Bartley PA; Ross DM; Latham S; Martin-Harris MH; Budgen B; Wilczek V; Branford S; Hughes TP; Morley AA
    Int J Lab Hematol; 2010 Dec; 32(6 Pt 1):e222-8. PubMed ID: 20491997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluctuation of BCR-ABL1 qPCR
    Kuan JW; Chang KM; Phan CL; Wong SP; Lim SM; Toh SG; Loh WK
    Med J Malaysia; 2021 May; 76(3):414-416. PubMed ID: 34031342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deep molecular response in chronic myeloid leukemia: the new goal of therapy?
    Mahon FX; Etienne G
    Clin Cancer Res; 2014 Jan; 20(2):310-22. PubMed ID: 24166905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.